Medicina

Journal Browser

► Journal Browser

Advances in Cancer Multimodal Approaches: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies, 2nd Edition

Special Issue Editors
Special Issue Information
Keywords
Related Special Issue
Published Papers

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 329

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

Cancer is the leading cause of death worldwide, accounting for more than 10 million deaths each year and an even higher number of patients that are diagnosed with this disease undergoing various procedures. This is the consequence of the increased number of risk factors that have become present in our lives in recent decades, such as tobacco, obesity and various unhealthy food diets, alcohol, viral infections, exposure to certain chemicals or radiations, etc.

Our goal as medical practitioners or scientists is to obtain the best outcome for patients, from prophylactic procedures to a correct diagnosis, a specific multimodal treatment and rigorous follow-up. All these have significantly improved in recent years because of a better understanding of the genetic and molecular mechanisms of cancer development, the emergence of new technologies in cancer detection or surgical techniques, and breakthroughs in oncological therapies.

The aim of this Special Issue is to highlight new insights into advances of cancer multimodal approaches. Therefore, we encourage authors to submit their systematic reviews, meta-analyses, clinical outcome studies or new surgical techniques and oncological therapies regarding this subject.

Dr. Daniel Alin Cristian
Prof. Dr. Valentin Titus Grigorean
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (1 paper)

Research

12 pages, 1531 KiB

Open AccessArticle

Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience

by Nebi Serkan Demirci, Eyyup Cavdar, Nuriye Yildirim Ozdemir, Sinemis Yuksel, Yakup Iriagac, Gokmen Umut Erdem, Hatice Odabas, Ilhan Hacibekiroglu, Mustafa Karaagac, Mahmut Ucar, Banu Ozturk and Yakup Bozkaya

Medicina 2024, 60(5), 818; https://doi.org/10.3390/medicina60050818 - 16 May 2024

Viewed by 190

Abstract

Background and Objectives: In ampullary cancer, 5-year survival rates are 30–50%, even with optimal resection and perioperative systemic therapies. We sought to determine the important clinicopathological features and adjuvant treatments in terms of the prognosis of patients with operable-stage ampullary carcinomas. Materials and Methods: We included 197 patients who underwent pancreaticoduodenectomy to treat ampullary carcinomas between December 2003 and May 2019. Demographics, clinical features, treatments, and outcomes/survival were analyzed. Results: The median disease-free survival (mDFS) and median overall survival (mOS) were 40.9 vs. 63.4 months, respectively. The mDFS was significantly lower in patients with lymphovascular invasion (p < 0.001) and lymph node involvement (p = 0.027). Potential predictors of decreased OS on univariate analysis included age ≥ 50 years (p = 0.045), poor performance status (p = 0.048), weight loss (p = 0.045), T3–T4 tumors (p = 0.018), surgical margin positivity (p = 0.01), lymph node involvement (p = 0.001), lymphovascular invasion (p < 0.001), perineural invasion (p = 0.007), and poor histological grade (p = 0.042). For the multivariate analysis, only nodal status (hazard ratio [HR]1.98; 95% confidence interval [CI], 1.08–3.65; p = 0.027) and surgical margin status (HR 2.61; 95% CI, 1.09–6.24; p = 0.03) were associated with OS. Conclusions: Nodal status and a positive surgical margin were independent predictors of a poor mOS for patients with ampullary carcinomas. Additional studies are required to explore the role of adjuvant therapy in patients with ampullary carcinomas. Full article

(This article belongs to the Special Issue Advances in Cancer Multimodal Approaches: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies, 2nd Edition)

► Show Figures